---
title: "Research Alert: CFRA Lifts Rating On Shares Of Teva Pharmaceutical Industries To Buy From Hold"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284832437.md"
description: "CFRA has upgraded Teva Pharmaceutical Industries' rating from Hold to Buy, raising the target price to $42 from $36. The analysts adjusted the 2026 EPS estimate down to $2.11 due to the Emalex acquisition impact but maintained the 2027 EPS estimate at $3.09. Teva's Q1 performance exceeded expectations, driven by strong growth in innovative products. The $700M Emalex acquisition, expected to close in Q3, is seen as a strategic move to enhance Teva's neuroscience pipeline with a new treatment for Tourette syndrome."
datetime: "2026-04-30T20:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284832437.md)
  - [en](https://longbridge.com/en/news/284832437.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284832437.md)
---

# Research Alert: CFRA Lifts Rating On Shares Of Teva Pharmaceutical Industries To Buy From Hold

04:30 PM EDT, 04/30/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $42 from $36, 13.6x our 2027 EPS forecast of $3.09, aboveTEVA's historical forward P/E average, justified in our view, by its improving growth prospects. We lower our 2026 EPS estimate to $2.11 from $2.77 to adjust for the Emalex acquisition impact. We keep our 2027 EPS estimate at $3.09. Teva reported a solid Q1, beating expectations, driven by the continued strong performance of its innovative growth engines (AUSTEDO, AJOVY, and UZEDY) which collectively grew 41% and are successfully offsetting the anticipated revenue decline from the loss of exclusivity for the generic REVLIMID. The newly announced $700M Emalex acquisition, expected to close in Q3, is a significant strategic move, and a major positive, in our view. The deal will bring the NDA-ready, first-in-class lead asset Ecopipam to treat Tourette syndrome, which has a significant unmet need, into Teva's neuroscience pipeline. We think the acquisition can accelerate TEVA's shift toward innovative, high-margin products.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)

## Related News & Research

- [Biopharmaceutical Company Teva to Bring Innovative Migraine Treatment to China With NeuroGen Pharma](https://longbridge.com/en/news/283652385.md)
- [Teva Lowers 2026 Non-GAAP Operating Profit Outlook On Emalex Deal; On Track To Achieve 2027 Targets](https://longbridge.com/en/news/284568185.md)
- [Research Alert: CFRA Upgrades Opinion On Shares Of Tractor Supply Company To Buy From Hold](https://longbridge.com/en/news/287097602.md)
- [CFRA downgrades Bank of America (BAC) to a Hold](https://longbridge.com/en/news/286974239.md)
- [Research Alert: CFRA Raises Opinion On Shares Of Whirlpool Corp. To Buy From Hold](https://longbridge.com/en/news/286301976.md)